← Claudine Duvivier

Papers by Claudine Duvivier

Page 2 · newest first

51. Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohortBMC Infectious Diseases · 2019
52. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort studyPLoS ONE · 2019
53. Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohortPLoS ONE · 2018
54. Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case–Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4)JAIDS Journal of Acquired Immune Deficiency Syndromes · 2018
55. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)Journal of Antimicrobial Chemotherapy · 2018
56. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patientsPLoS ONE · 2018
57. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohortAIDS · 2018
58. Factors associated with deaths from suicide in a French nationwide HIV‐infected cohortHIV Medicine · 2018
59. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-studyJournal of Antimicrobial Chemotherapy · 2018
60. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)Journal of Antimicrobial Chemotherapy · 2018
61. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIVAIDS · 2018
62. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in EuropeHIV Medicine · 2018
63. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to eliminationBMC Medicine · 2017
64. Potential Role of Vδ2+ γδ T Cells in Regulation of Immune Activation in Primary HIV InfectionFrontiers in Immunology · 2017
65. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimenJournal of Antimicrobial Chemotherapy · 2017
66. Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppressionJournal of Antimicrobial Chemotherapy · 2017
67. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretroviralsJournal of Antimicrobial Chemotherapy · 2017
68. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort studyPLoS ONE · 2017
69. CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cARTPLoS ONE · 2016
70. First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.Medicine · 2016
71. Hepatitis C treatment initiation in HIV-HCV coinfected patientsBMC Infectious Diseases · 2016
72. Aortic stiffness aging is influenced by past profound immunodeficiency in HIV-infected individualsJournal of Hypertension · 2016
73. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial)Journal of Antimicrobial Chemotherapy · 2016
74. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patientsScandinavian Journal of Infectious Diseases · 2016
75. Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control StudyPLoS ONE · 2015
76. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokersAIDS · 2015
77. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsPLoS ONE · 2015
78. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 studyJournal of Antimicrobial Chemotherapy · 2015
79. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remissionJournal of Antimicrobial Chemotherapy · 2015
80. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)Clinical Infectious Diseases · 2015
81. Dolutegravir in HIV-2–Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient ProgramClinical Infectious Diseases · 2015
82. Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase regionJournal of Antimicrobial Chemotherapy · 2015
83. Claudin‐1 gene variants and susceptibility to hepatitis C infection in HIV‐1 infected intravenous drug users (an ANRS case‐control study)Journal of Medical Virology · 2015
84. Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4)International Journal of Epidemiology · 2014
85. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyThe Journal of Infectious Diseases · 2014
86. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenzJournal of Antimicrobial Chemotherapy · 2013
87. A Single HIV-1 Cluster and a Skewed Immune Homeostasis Drive the Early Spread of HIV among Resting CD4+ Cell Subsets within One Month Post-InfectionPLoS ONE · 2013
88. Incidence of HIV-Related Anal Cancer Remains Increased Despite Long-Term Combined Antiretroviral Treatment: Results From the French Hospital Database on HIVJournal of Clinical Oncology · 2012
89. Switching to darunavir/ritonavir 800/100 mg once‐daily containing regimen maintains virological control in fully suppressed pre‐treated patients infected with HIV‐1Journal of Medical Virology · 2012
90. Boosted protease inhibitor monotherapy as a maintenance strategyAIDS · 2012
91. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugsJournal of Antimicrobial Chemotherapy · 2012
92. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patientsAIDS · 2011
93. Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir MonotherapyThe Journal of Infectious Diseases · 2011
94. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesisBlood · 2011
95. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010BMC Infectious Diseases · 2010
96. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS · 2010
97. Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or MonotherapyAntimicrobial Agents and Chemotherapy · 2010
98. Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive DrugsAmerican Journal of Transplantation · 2009
99. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patientsAIDS · 2009
100. Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009